Cytek Biosciences Inc
F:8EQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cytek Biosciences Inc
F:8EQ
|
US |
|
First Financial Corp
NASDAQ:THFF
|
US |
|
Vardhman Textiles Ltd
NSE:VTL
|
IN |
|
Nongfu Spring Co Ltd
OTC:NNFSF
|
CN |
|
G
|
GAIL (India) Ltd
BSE:532155
|
IN |
|
P
|
Public Service Enterprise Group Inc
F:PSE
|
US |
|
M
|
Metso Oyj
OMXH:METSO
|
FI |
|
S
|
Solar Industries India Ltd
BSE:532725
|
IN |
|
Gilead Sciences Inc
MIL:1GILD
|
US |
|
W
|
Walgreens Boots Alliance Inc
SWB:W8A
|
US |
Cytek Biosciences Inc
Cytek Biosciences makes instruments and software used in flow cytometry, a lab method that analyzes cells by passing them in front of lasers and detectors. Its main products are cell-analyzing instruments, reagents, and data-analysis tools that help researchers and labs measure many properties of single cells at once. The company’s systems are used in life-science research, drug development, and clinical and translational labs that need detailed cell analysis. Cytek sells mainly to academic labs, biotech and pharmaceutical companies, and clinical research organizations. It makes money by selling instruments upfront and then earning recurring revenue from reagents, service contracts, and software tied to those systems. That model gives it both one-time equipment sales and repeat business from customers who keep using the platform for ongoing experiments. What makes Cytek different is its focus on high-parameter flow cytometry, which lets scientists collect more information from each cell than many older systems. In practice, it sits between the makers of lab equipment and the researchers who need precise cell data, with its hardware, reagents, and analysis software designed to work together as a single workflow.
Cytek Biosciences makes instruments and software used in flow cytometry, a lab method that analyzes cells by passing them in front of lasers and detectors. Its main products are cell-analyzing instruments, reagents, and data-analysis tools that help researchers and labs measure many properties of single cells at once. The company’s systems are used in life-science research, drug development, and clinical and translational labs that need detailed cell analysis.
Cytek sells mainly to academic labs, biotech and pharmaceutical companies, and clinical research organizations. It makes money by selling instruments upfront and then earning recurring revenue from reagents, service contracts, and software tied to those systems. That model gives it both one-time equipment sales and repeat business from customers who keep using the platform for ongoing experiments.
What makes Cytek different is its focus on high-parameter flow cytometry, which lets scientists collect more information from each cell than many older systems. In practice, it sits between the makers of lab equipment and the researchers who need precise cell data, with its hardware, reagents, and analysis software designed to work together as a single workflow.
Revenue: Cytek reported first-quarter revenue of $44.1 million, up 6% year over year, with strength in the U.S. offset by softer EMEA and APAC results.
Recurring mix: Reagents and service continued to gain importance, with recurring revenue reaching 35% of total revenue on a trailing 12-month basis and growing 19% year over year.
Guidance: Management reaffirmed full-year 2026 revenue guidance of $205 million to $212 million and said it expects positive adjusted EBITDA for the full year.
U.S. rebound: U.S. revenue rose 32%, driven by stronger instrument demand from academic, government and biopharma customers, including a strong quarter for Aurora Evo.
Headwinds: EMEA was hurt by conflict-related disruption and an end-of-quarter shipping delay, while APAC declined mainly because China orders had been pulled forward into last year.
Costs: Gross margin held relatively steady, but higher legal expenses tied to patent litigation pushed general and administrative expense higher and widened the quarterly loss.
